Ekso Bionics Makes Strides with CMS Reimbursement and Launches EksoHealth Personal Program
Ekso Bionics Holdings Inc, a leading exoskeleton technology company, has recently announced the receipt of initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton. This marks a significant milestone for the company as it continues to expand its reach in the healthcare industry.
The CMS reimbursement validates the efficacy and value of Ekso Bionics’ exoskeleton technology in improving the lives of individuals with mobility limitations. The Ekso Indego Personal is designed to provide assistance to those with spinal cord injuries and other neurological impairments, enabling them to regain mobility and independence.
To further support individuals in accessing exoskeleton technology, Ekso Bionics has also launched the EksoHealth Personal program. This program aims to assist individuals in navigating the complexities of insurance coverage and reimbursement for exoskeleton devices. By providing guidance and support, EksoHealth Personal aims to make exoskeleton technology more accessible to those who can benefit from it.
Despite these positive developments, Ekso Bionics Holdings Inc shares are currently trading on the NASDAQ below its 52-week average. The company’s stock has experienced a 26.5% decrease, reflecting market uncertainties and investor sentiments. Additionally, Ekso Bionics recorded a net loss of $12 million during the twelve months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -42.83%.However, it is worth noting that within the Capital Goods sector, Ekso Bionics is still making progress. While the ROA ranking for the company is lower compared to 164 other companies in the sector, with a higher return on assets, its overall ranking has advanced in the Jun 30, 2024 quarter. Ekso Bionics’ ROA ranking has improved from 3171 in the first quarter of 2024 to 2289 in the second quarter, indicating potential growth and positive prospects.
The receipt of CMS reimbursement for the Ekso Indego Personal, coupled with the launch of the EksoHealth Personal program, demonstrates Ekso Bionics’ commitment to advancing exoskeleton technology and improving the quality of life for individuals with mobility limitations. As the company continues to innovate and expand its market presence, it is poised to make a significant impact in the healthcare industry.
Comments